UCB SA (UCB.VI)
| Previous close | 136.80 |
| Open | 137.80 |
| Bid | 136.85 x N/A |
| Ask | 138.20 x N/A |
| Day's range | 137.80 - 137.80 |
| 52-week range | 66.04 - 139.35 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 26.151B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 78.30 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.36 (0.99%) |
| Ex-dividend date | 26 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia
UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of FINTEPLA® (fenfluramine) in reducing the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) among patients with developmental and epileptic encephalopathies (DEEs). This analysis highlighted a significant reduction in both GTCS and TCS across various DEEs adding to the already established data from the FINTEPLA
- PR Newswire
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels
UCB, a global biopharmaceutical company, will present results from three studies for CIMZIA® (certolizumab pegol), a PEGylated fragment crystalized (Fc)-free tumor necrosis factor inhibitor (TNFi), for women of childbearing age living with chronic immune-mediated diseases and people with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels.1,2,3 These data will be presented at the European Congress of Rheumatology, EULAR 2024, and provide evidence to inform personalized treatment dec
- PR Newswire
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
UCB, a global biopharmaceutical company, today announced the first presentation of two-year data from the Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension (OLE), BE MOVING, evaluating BIMZELX, an interleukin (IL)-17A and IL-17F inhibitor, in the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis. The impact of BIMZELX treatment on two-year radiographic progression in
